TransMedics Group (NASDAQ:TMDX) Reaches New 1-Year Low – Here’s Why

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price reached a new 52-week low during trading on Thursday . The company traded as low as $60.40 and last traded at $60.88, with a volume of 1588704 shares. The stock had previously closed at $65.71.

Wall Street Analysts Forecast Growth

TMDX has been the topic of several recent analyst reports. TD Cowen cut their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research report on Tuesday. Oppenheimer reiterated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Performance

The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a market cap of $2.04 billion, a P/E ratio of 64.77 and a beta of 2.06. The firm’s 50-day moving average is $91.40 and its two-hundred day moving average is $129.80.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.12) EPS. As a group, research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,417 shares of company stock worth $2,240,738. 7.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently made changes to their positions in the business. International Assets Investment Management LLC bought a new position in TransMedics Group in the 2nd quarter worth approximately $47,000. USA Financial Formulas bought a new position in TransMedics Group during the third quarter worth $55,000. Quarry LP increased its position in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares during the period. National Bank of Canada FI boosted its holdings in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares during the period. Finally, Signaturefd LLC grew its position in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.